SanMelix Laboratories
Helping You Heal with Honey
HOLLYWOOD, FL
Consumer Products
Pharmaceutical
Our Goal is Simple, Faster and Healthier Healing
$552,068
raised
949
Investors
12
Days Left
$0.60
Price per Share
$6.56M
Valuation
Equity
Offering Type
$249.60
Min. Investment
Bonus Rewards
Get rewarded for investing more into SanMelix Laboratories
$249+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500+
Investment
5% Bonus Shares
If you invest $500+, you will receive 5% bonus shares
$1,000+
Investment
10% Bonus Shares
If you invest $1,000+, you will receive 10% bonus shares
$2,500+
Investment
15% Bonus Shares
If you invest $2,500+, you will receive 15% bonus shares
$5,000+
Investment
20% Bonus Shares
If you invest $5,000+, you will receive 20% bonus shares
Reasons to Invest
First MGO honey-based wound dressing patented formulations with anticipated FDA microbial claim
Our advanced wound care dressings will address the antimicrobial resistance (AMR) crisis
Our bioactive buckwheat honey products promote faster and healthier healing
Bringing faster healthier healing to all
Invest in SanMelix
Using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements, SanMelix has created a product that aids in the healing of acute, chronic and minor wounds. With IP protection on our BEECure™ M dressing and other pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive wound care products can be used in a host of settings and situations. We have created over-the-counter (OTC) skin care products such as ointments and creams designed to help in the healing of minor burns, scrapes, radiodermatitis and more. Our products will also be used for advanced wound care in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments.
We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve the lives of patients and help speed up the healing process using the natural therapeutic properties that already exist in buckwheat honey. Honey has been used in medicine since 8000 BC because of its unique healing properties and with our team of doctors and scientists, we have enhanced it through the use of broad-spectrum antimicrobials. Dr. Sabacinski developed the BEECure™ dressings to help prevent the dangerous side effects and adverse drug interactions that often arise with the use of predominantly synthetic pharmaceuticals.
Dr. Sabacinski has been working in the wound care space for over thirty years, and he knows the patients’ needs for a product that encourages fast wound closure and provides protection from bacteria and infection. Our mission at SanMelix is to help people. We want to give caregivers, physicians, and the general public the ability to heal wounds using a natural product that’s been used for centuries. At SanMelix, the proof is in our buckwheat honey.
With the funds raised through StartEngine, we plan to complete the testing on our products as well as prepare inventory. Our first product launch will be our OTC cosmetic line. We have an agreement with a European company to license or purchase the CE Marked formulation for our first buckwheat honey skin care product and will use the funds to help complete this arrangement.
The entire population requires wound care
- The global bioactive wound care market in 2018 was 8.38 billion and is projected to reach $13.5 billion by 2026
- 50 million people annually are affected by hard to close wounds
- Chronic wounds affect over 5.7 million patients in the U.S. alone and are estimated to cost $20 billion annually, thus impacting the market growth positively
- Due to Antimicrobial Resistance (AMR) 700,000+ people die globally, and it’s projected to increase to 10 million people per year by 2050
- Everyday people require wound care therapies for minor cuts, scrapes, abrasions, and rashes
But synthetic wound care products have issues
- Potentially dangerous side effects can occur from entirely synthetic wound care products
- There are environmental consequences to the manufacturing of chemical based products
- There are multi drug resistant super infections such as MRSA and A. baumannii
- Skin grafts and skin substitutes require repeated application
- There are few effective therapies for radiotherapy, laser therapy and minor thermal burns
- Often severe wounds can result in amputations
Using natural products we can solve them
- Our BEECure™ M (buckwheat honey MGO) patented formulation reduces microbial growth and provides a barrier to prevent life threatening bacteria (MRSA) from penetrating the dressing
- Case studies using BEECure ™ M illustrated accelerated healing and skin regeneration on severe limb threatening wounds
- Need for fewer applications of skin grafts and skin substitute when honey dressings are applied to graft
- Buckwheat honey reduces scarring and inflammation related to radiotherapy, laser therapy and minor thermal burns
- SanMelix OTC buckwheat honey formulations would be considered a first aid antibiotic/antiseptic/antimicrobial to treat minor cuts, scrapes and burns
- Greener product in use and in manufacturing
We create products using Buckwheat Honey
We are focusing on the unique medicinal properties of Buckwheat Honey for tissue regeneration and accelerated healing. Our bioactive buckwheat honey formulations demonstrate intrinsic healing activity with anti-microbial additives to prevent infection. SanMelix has a patent on its BEECure™ M formulation and Dr. Sabacinski has co-invented 2 additional patent pending natural Buckwheat Honey BEECure™ medical devices which also demonstrated superior clinical outcomes. Studies have proven that buckwheat honey has superior medicinal properties to Manuka honey and other natural remedies. Our products also have higher standardization and broader spectrum anti-microbial activity achieving consistent clinical outcomes. Buckwheat honey also has higher anti-inflammatory and anti-oxidant activities than other products currently being used.
The anti-oxidant properties in Buckwheat honey assist in wound closure and help to stimulate the wound healing process. This means wounds are healing faster and better without the risk of further complications that could be a great hindrance to the lives of patients. Our Buckwheat honey patented formulation creates a microbial barrier to prevent life-threatening bacteria from penetrating through the dressing while it is in use. The nutrients in the honey help spur tissue regeneration because it contains large quantities of easily assailable sugars, amino acids, vitamins, specifically vitamin C. Our products are made to heal chronic and difficult to close wounds.
Our Products in Use
Our BEECure™ products can be used for a wide variety of skin irritations and advanced wound care. Because of the antimicrobial claim in our wound care dressings, they will be instrumental in the treatment and healing of:
- Ulcers, diabetic and otherwise
- Skin grafts
- Burns
- Trauma and triage
- And more!
Previously we were working in tandem with Trauma insight, who formed a CRADA with the Airforce to perform the 510(k) performance and microbial barrier testing. Due to the Coronavirus Disease 2019 (“COVID-19”) our biocompatibility testing with the Air Force was postponed after the Air Force had completed some of the initial in vitro 510(k) testing. We are establishing relationships with additional GLP testing facilities to conduct the remaining 510(k) testing. Once we receive our FDA pre-market clearance, we anticipate working with Trauma Insight as our CRO for clinical trials.
The advanced wound care BEECure™ M dressing is currently in the testing phase. The radiodermatitis cream is in the testing phase and anticipated to launch in Q4, 2020. All other products have not yet been developed.
Advanced Wound Care (AWC)
BEECure™ M wound dressings
BEECure™ I wound dressings
BEECure™ B wound dressings
*BEECure I and BEECure B wound dressings are currently in development. BeeCure M wound dressing are in testing phases
Over The Counter (OTC)
BEECure™ R (radiodermatitis)
BEECure ™ Skin Care
BEECure™ Minor Burns
BEECure™ DFU Cream
*BEECure™ R is currently in development.
The difference is in the ingredients
Although manuka honey is the most commonly used honey-based wound treatment on the market, studies have shown that buckwheat honey has superior inherent healing properties when compared to manuka honey due to its higher anti-inflammatory and higher anti-oxidant activities. In addition, SanMelix’s advanced wound care products have been fortified with antimicrobials to ensure a higher standardized and broader spectrum antibacterial activity. Our patented formulation utilized in our AWC dressings permits SanMelix to launch one of the first bioactive honey dressing to make an antimicrobial claim in the U.S. Our honey dressing is currently in development.. Our bioactive dressing will be for any wound type of any depth and severity. The dressing will prevent biofilms from forming, control wound odor, reduce pain and treatment time while being cost-effective and more environmentally sound.
Additionally, there will be improved skin and tissue regeneration and debriding action. This prevents the necessity for excess skin grafts or skins substitutes, which run the added risk of infection or rejection. Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogens.
The bottom line is that our enhanced Buckwheat honey dressings and ointments are making the lives of patients and doctors easier. We are here to assist in the healing process and make a painful experience as painless as possible. We have seen firsthand the need for such products as the ones we've been creating and know that our BEECure™ products are going to be a big step forward in changing the lives of many.
Natural ingredients that reduce inflammation and rehydrate your skin
Securing powerful partnerships
Through our previous collaboration with our Contract Research Organization, Trauma Insight, we were able to establish a collaboration with the Air Force in order to conduct preclinical research that supported the 510(k) product testing. Some of our in-vitro testing was completed in November 2019; however, due to the Coronavirus Disease 2019 (“COVID-19”), the remaining 510(k) testing was postponed by the Air Force. We are establishing relationships with additional GLP testing facilities to complete our 510(k) pre-market clearance testing.
We are looking to continue testing our advanced wound care products to obtain 510(k) pre-market clearance from the FDA and to continue prosecuting our other two patent pending formulation applications. We have an agreement with a European company to distribute its existing buckwheat honey CE Mark products for radio-dermatitis and laser therapy induced skin reactions and secure our main authentic raw buckwheat honey supplier.
On top of this, we are negotiating with other GMPs to contract manufacture our skin care products. We will continue to test, research and expand our products utilizing world renown physicians and scientists.
We are thrilled about all that lies ahead for the SanMelix team and the effect our nature-based products will have on healing.
A team of experts
SanMelix is proud to have some of the most experienced and widely renowned minds behind our products. Dr. Kenneth Sabacinski has worked in the advanced wound care space for over thirty years. He is a podiatric physician who started his training at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. People come from all over the world to see him for treatment of limb and life-threatening wounds including diabetic-related foot ulcers.
In addition to co-founder Dr. Sabacinski, our medical team of experts includes Dr. Jason Green, D.O. Board Certified Dermatologist, and COL (ret) George E. Peoples, MD, FACS. Dr. Green is our Advisory Board Director and is currently performing product testing of our initial CE Mark skin care product for radiodermatitis. Dr. George Peoples is the founder of Trauma Insight. Through his military career as a staff surgeon at a level I trauma center and multiple combat deployments, Dr. Peoples has extensive trauma experience and has developed close relationships with some of the most prominent military and civilian trauma and critical care physicians in the country.
Diana Sabacinksi and John Kaufman also serve as directors. Diana has over 25 years of accounting experience across a swath of fields, as well as starting her career in a Big 4 CPA international accounting firm. John Kaufman is the founder of InteSec Group Fla LLC. He also founded Be Power Tech Inc. and served as its Chairman, Director, co-patent holder, and consultant. Together, the directors boast business acumen and scientific prowess and along with partnerships with other leading researchers and scientists, SanMelix is proud to have such strong and exciting leaders at the helm.
Dr. Kenneth Sabacinski
Diana Sabacinksi
Bringing buckwheat honey's healing power to skin care
Our skin care product line will provide honey based ointment for a myriad conditions like radiodermatitis, rashes, acne and much more. We have completed skin irritation tests on our radiodermatitis cream and anticipate launching in Q4,2020. Our initial skin care product will be regulated under the United States Federal Food, Drug, and Cosmetic Act. The FDA OTC monograph program will use the patent pending formulations while using already recognized FDA products to enhance our creams and ointments.
BEECure™ products can be used for or as a(an):
- Acne Treatment
- Antiseptic Bandage
- Diabetic foot cream
- Burn Care Ointment
- Radiodermatitis
- Eczema
- Eye drops
- Eczemema
- Diaper Rash
- And more!
What people are saying
Help us improve lives
There are over 50 million reported cases globally of patients suffering from hard-to-close wounds. 15% of these are diabetic foot ulcers that eventually lead to amputation. SanMelix BEECure™ bioactive wound care products are here to treat everything from a minor scrape to a severe wound and everything in between. Using our unique enhanced Buckwheat honey formulations fortified with microbial barriers, we are treating all types of dermal afflictions by speeding up the healing process and reducing pain and the risk of infection.
Honey is a product that's been used all throughout history as a healing and restorative agent, and we are harnessing its natural powers and using our years of scientific and medicinal studies to enhance it. We are regulating it to make it safe for hospital use, as well selling it OTC to the average consumer. Everyone should be able to experience the benefits of the BEECure™ Buckwheat honey products.
Our customers will include the VA & DoD, medical supply distributors, physician networks, hospitals, SNFs as well as indirect sales channel for private label/ white label for OTC opportunities. We will market directly to OTC consumers through digital marketing and social media. We are capitalizing on a market that has been desperately in need of a natural and safe product that promotes healing and tissue growth among many other benefits.
We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve patients' lives in need of healing with our innovative bioactive wound care and skin care products.
Offering Summary
Company | : | SanMelix Laboratories, Inc. |
Corporate Address | : | 1150 North 35th Avenue Suite 225, HOLLYWOOD, FL 33021 |
Offering Minimum | : | $9,999.60 |
Offering Maximum | : | $1,069,998.00 |
Minimum Investment Amount(per investor) | : | $249.60 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock NV |
Minimum Number of Shares Offered | : | 16,666 |
Maximum Number of Shares Offered | : | 1,783,330 |
Price per Share | : | $0.60 |
Pre-Money Valuation | : | $6,561,600.00 |
*Maximum subject to adjustment for bonus shares. See Bonus info below
Investment Bonuses
If you invest $500+, you will receive 5% bonus shares.
If you invest $1,000+, you will receive 10% bonus shares.
If you invest $2,500+, you will receive 15% bonus shares.
If you invest $5,000+, you will receive 20% bonus shares.
The 10% Bonus for StartEngine Shareholders
SanMelix Laboratories, Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 in StartEngine's own offerings.
StartEngine shareholders who invested $1,000 or more in any StartEngine offering will receive a 10% bonus on this offering. This means you will receive a bonus for any shares you purchase. For example, if you buy 100 shares of Common Stock NV at $0.60 / share, you will receive 110 Common Stock NV shares, meaning you'll own 110 shares for $60. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors received their countersigned StartEngine Crowdfunding Inc. subscription agreement.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$252,210.00
USD
$259,432.00
USD
Cash And Cash Equivalents
$51,318.00
USD
$78,623.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$18,738.00
USD
$4,272.00
USD
Long Term Debt
$0.00
USD
$0.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
-$183,696.00
USD
-$290,978.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
900 Strong!
9 days agoIt’s been another great week for SanMelix as we reached over 900 investors, and over $18k in 2 days this past weekend! Let’s keep the momentum going and share our story with your friends and family. We are so thankful to YOU, our investors, and family. Stayed tuned for updates as we prepare to launch our radiodermatitis launch in Q4. Again, thank you for your support!
Stay safe and Bee well,
Diana
Did you know?
14 days agoHi Everyone,
The global Radiodermatitis market is expected to grow at a compound annual growth rate of 4.0% from 2018 to 2025 to reach USD 442.1 million by 2025, leading to an unprecedented demand for radiodermatitis treatment products. Our product launch is a step to increase product penetration, and cater to a larger patient base. Already invested and planning to add more? Now is a great time to act! Please share our message with your network of friends, family and followers.
Stay safe,
The SanMelix Team.
Latest Buzz!
22 days agoHi everyone,
Congratulations to all our investors and community as today we surpassed a major milestone, over $500,000 in commitments. Thank you for making our campaign such a success. Our goal is to max out the allowable limit, but we need help. If you haven’t yet, don’t miss the opportunity to own a piece of a company that is creating a product that aids in the healing of acute, chronic and minor wounds. Please share our journey with friends and family.
Stay safe!
The SanMelix Team
International Patent!
28 days agoHi everyone,
We are excited to announce we just received a notice of allowance for our international patent. In addition, we are moving ahead with the launch of our radiodermatitis cream. Stayed tuned for more updates. We truly thank you for your support, trust and engagement. Please continue to share our story with friends and family so we can reach our $500k goal!
All the best,
Diana
Happy 4th!
about 1 month agoHi everyone,
We are thrilled to announce we received our 2nd patent this week. Thanks very much to the 700+ investors who have joined our investor team already, we really wouldn't be here without the support of our investors, so we sincerely appreciate it. Again, we have exciting products in the works, so please stay tuned. We wish you and your loved ones a happy and safe 4th!
The SanMelix Team
Heading to 500K
about 1 month agoHi everyone,
We are very excited our campaign is still building momentum. Because of you, we had over $64K in commitments for June. We thank you for believing in what we are trying to achieve, and stepping in to join us on this journey. Some of our new investors may have received a notice to reconfirm their investments as we had material changes. If you have not already logged back into your account to ensure you are still participating in our journey, please do it today. Again, thank you for your continued support and commitment.
Stay safe,
Diana
Notice of Funds Disbursement
about 1 month ago[The following is an automated notice from the StartEngine team].
Hello!
As you might know, SanMelix Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SanMelix Laboratories be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
Moving Forth
about 2 months agoHello all,
This week we entered into an agreement with Product Launchers a company that fuses timeless and proven product launching principles with modern, effective sales and marketing techniques to help us grow both in-store and online. Product Launchers will launch our radiodermatitis cream on Amazon in Q4. Please share this exciting news with your friends and family, and if you are new to our family, remember to log back into your account to reconfirm your investment.
Bee Well,
Diana
Exciting News!
about 2 months agoHello,
Today we have surpassed another milestone with over $450k invested in our campaign. We sincerely thank you all for your support. Please encourage family and friends to invest as well. Our campaign is updated to reflect the launching of our radiodermatitis product in Q4. lookout for an email from StartEngine that will require reconfirmation of your investment.
Bee well,
The SanMelix Team.
Notice of Material Change in Offering
about 2 months ago[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the SanMelix Laboratories offering. Here's an excerpt describing the specifics of the change:
SanMelix updated their campaign page and extended their campaign.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
Hello, 
Comments ({{profileCtrl.startup.comments_count}} total)
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}